Selected Publications
Sharma A, Triplett BM, Chi L, Cross SJ, Zheng Y, Arnold PY. Donor-derived anti-HLA antibodies in a haploidentical hematopoietic cell transplant recipient shortly after transplant. Hum Immunol Jul 1;85(4):110829, 2024.
Kearney L, Bosnick R, Phillips H, Ghio A, Cullen D, Sweat L, Zheng Y. Optimization of single-needle red cell exchange in patients with sickle cell disease. J Clin Apher Jun 1;39(3):e22118, 2024.
Chang TC, Yu J, Wang Z, Hankins JS, Weiss MJ, Wu G, Westhoff CM, Chou ST, Zheng Y. Machine learning to optimize automated RH genotyping using whole-exome sequencing data. Blood Adv March 24, 2024.
Israelyan N, Vege S, Friedman DF, Zhang Z, Uter S, Fasano RM, Yee M, Piccone C, Kelly S, Hankins JS, Zheng Y, Westhoff CM, Chou ST. RH genotypes and red cell alloimmunization rates in chronically transfused patients with sickle cell disease: A multisite study in the USA. Transfusion Jan 30, 2024.
Zheng Y, Yang W, Estepp J, Pei D, Cheng C, Takemoto CM, Inaba H, Jeha S, Pui CH, Relling MV, Karol SE. Genomic analysis of venous thrombosis in children with acute lymphoblastic leukemia from diverse ancestries. Haematologica Jan 1;109(1):53-59, 2024.
Zheng Y, Gossett JM, Chen PL, Barton M, Ryan M, Yu J, Kang G, Hankins JS, Chou ST. Proinflammatory state promotes red blood cell alloimmunization in pediatric patients with sickle cell disease. Blood Adv Sept 12;7(17)4799-4808, 2023.
Sharma A, Boelens JJ, Cancio M, Hankins JS, Bhad P, Azizy M, Lewandowski A, Zhao X, Chitnis S, Peddinti R, Zheng Y, Kapoor N, Ciceri F, Maclachlan T, Yang Y, Liu Y, Yuan J, Naumann U, Yu VWC, Stevenson SC, De Vita S, LaBelle JL. CRISPR-Cas9 editing of the HBG1 and HBG2 promoters to treat sickle cell disease. N Engl J Med Aug 31;389(9):820-832, 2023.
Christakopoulos GE, Walker KN, Smith J, Takemoto CM, Zheng Y, Pui CH, Ribeiro RC, Wang L, Pounds SB, Rubnitz JE, Inaba H. Clinical characteristics and outcomes of children with newly diagnosed acute myeloid leukemia and hyperleukocytosis managed with different cytoreductive methods. Cancer June 15;129(12):1873-1884, 2023.
Melo-Cardenas J, Bezavada L, Crawford JC, Gurbuxani S, Cotton A, Kang G, Gossett J, Marinaccio C, Weinberg R, Hoffman R, Migliaccio ARX, Zheng Y, Derecka M, Rinaldi CR, Crispino JD. IL-13/IL-4 signaling contributes to fibrotic progression of the myeloproliferative neoplasms. Blood Dec 29;140(26):2805-2817, 2022.
Sharma A, Leonard A, West K, Gossett JM, Uchida N, Panch S, Stroncek D, Poston L, Akel S, Hankins JS, Fitzhugh C, Hsieh MM, Kang G, Tisdale JF, Weiss MJ, Zheng Y. Optimizing haematopoietic stem and progenitor cell apheresis collection from plerixafor-mobilized patients with sickle cell disease. Br J Haematol June 23, 2022.
Sitthi-Amorn J, Denton E, Harper E, Carias D, Hashmi S, Bami S, Ast A, Landry T, Pettit KL Jr, Gorantla S, Vinitsky A, Zheng Y, Johnson LM. Improving blood product transfusion premedication plan documentation: A single-institution quality improvement effort. Pediatr Qual Saf 7(3):e572, 2022.
Doerfler PA, Sharma A, Porter JS, Zheng Y, Tisdale JF, Weiss MJ. Genetic therapies for the first molecular disease. J Clin Invest 131(8), 2021.
Zheng Y, Chou ST. Transfusion and cellular therapy in pediatric sickle cell disease. Clin Lab Med 41(1):101-109, 2021.
Zheng Y, Pei D, Sweat L, Ryan M, Mestemacher MA, Gann M, Cheng C, Geiger TL. Contribution of donor- and recipient-associated factors to allergic transfusion reactions to platelets. Transfusion 61(3):744-753, 2020.
Chang TC, Haupfear KM, Yu J, Rampersaud E, Sheehan VA, Flanagan JM, Hankins JS, Weiss MJ, Wu G, Vege S, Westhoff CM, Chou ST, Zheng Y. A novel algorithm comprehensively characterizes human RH genes using whole-genome sequencing data. Blood Adv 4(18):4347-4357, 2020.
Zheng Y, Tormey CA. The use of 4F-PCC to correct direct oral anticoagulant-induced coagulopathy: An observational analysis. Transfus Med. Apr 27, 2020. doi: 10.1111/tme.12683. [Epub ahead of print]
Zheng Y, Maitta RW. Alloimmunisation rates of sickle cell disease patients in the United States differ from those in other geographical regions. Transfus Med 26: 225-30, 2016.
Shameli A, Xiao W, Zheng Y, Shyu S, Sumodi J, Meyerson HJ, Harding CV, Maitta RW. A critical role for alpha-synuclein in development and function of T lymphocytes. Immunobiology 221:333-340, 2016.
Zheng Y, Hong H, Reeves HM, Maitta RW. Absolute immature platelet count helps differentiate thrombotic thrombocytopenic purpura from hypertension-induced thrombotic microangiopathy. Transfusion and Apheresis Science 51:54, 2014.
Zheng Y, George M, Chen F. Intravascular fasciitis involving the flank of a 21-year-old female: a case report and review of the literature. BMC Res Notes 7:118, 2014.
*Yasmin M, *Zheng Y, Cai D. Dysmegakaryocytopoiesis and maintaining platelet count in patients with plasma cell neoplasm. North American Journal of Medical Sciences 5:316, 2013. (* the two authors contributed equally)
Locke FL, Zha YY, Zheng Y, Driessens G, Gajewski TF. Conditional deletion of PTEN in peripheral T cells augments TCR-mediated activation but does not abrogate CD28 dependency or prevent anergy induction. J Immunol 191:1677, 2013.
Zheng Y, Zha Y, Spaapen RM, Mathew R, Barr K, Bendelac A, Gajewski TF. Egr2-dependent gene expression profiling and ChIP-Seq reveal novel biologic targets in T cell anergy. Mol Immunol 55:283, 2013.
Zheng Y, Zha Y, Driessens G, Locke F, Gajewski TF. Transcriptional regulator early growth response gene 2 (Egr2) is required for T cell anergy in vitro and in vivo. J Exp Med 209:2157, 2012.
Driessens G, Zheng Y, Locke F, Cannon JL, Gounari F, Gajewski TF. Beta-catenin inhibits T cell activation by selective interference with linker for activation of T cells-phospholipase C-gamma1 phosphorylation. J Immunol 186:784-790, 2010.
Driessens G, Zheng Y, Gajewski TF. Beta-catenin does not regulate memory T cell phenotype. Nat Med 16:513-514m 2010; author reply 514-515, 2010.
Zheng Y, Delgoffe GM, Meyer CF, Chan W, Powell JD. Anergic T cells are metabolically anergic. J Immunol 183:6095-6101, 2009.
Praveen K, Zheng Y, Rivas F, Gajewski TF. Protein kinase C theta focusing at the cSMAC is a consequence rather than cause of TCR signaling and is dependent on the MEK/ERK pathway. J Immunol 182:6022-6030, 2009.
Delgoffe GM, Kole TP, Zheng Y, Zarek PE, Matthews KL, Xiao B, Worley PF, Kozma SC, Powell JD. The mTOR kinase differentially regulates effector and regulatory T cell lineage commitment. Immunity 30:832-844, 2009.
Zheng Y, Zha Y, Gajewski TF. Molecular regulation of T-cell anergy. EMBO Reports 9:50-55, 2008.
Zheng Y, Collins SL, Lutz MA, Allen AN, Kole TP, Zarek PE, Powell JD. A role for mammalian target of rapamycin in regulating T cell activation versus anergy. J Immunol 178:2163-2170, 2007.
Powell JD, Zheng Y. Dissecting the mechanism of T-cell anergy with immunophilin ligands. Curr Opin Investig Drugs 7:1002-1007, 2006.
Allen A, Zheng Y, Gardner L, Safford M, Horton MR, Powell JD. The novel cyclophilin binding compound, sanglifehrin A, disassociates G1 cell cycle arrest from tolerance induction. J Immunol 172:4797-4803, 2004.
Last update: October 2024